Drugs & Targets First anti-PD-1 therapy approved for advanced gastric adenocarcinoma September 29, 2017Vol.43 No.36
Drugs & Targets Amgen and AbbVie agree to settlement allowing commercialization of Amgevita September 29, 2017Vol.43 No.36
Drugs & Targets FDA approves new label for Sun Pharma’s Odomzo for sustained duration of response in treatment of basal cell carcinoma September 29, 2017Vol.43 No.36
Lowy & Schiller at the Lasker Awards:The paradox of disease prevention, and how some scientists rise above their peers September 29, 2017Vol.43 No.36
Drugs & Targets EU approves AVEO’s Fotivda (tivozanib) for advanced renal cell carcinoma September 28, 2017Vol.43 No.32
Drugs & Targets Novartis’s Rydapt gets EU approval for AML and SM indications September 22, 2017Vol.43 No.35
Drugs & Targets FDA approves lower dose of cabazitaxel for prostate cancer September 22, 2017Vol.43 No.35
Drugs & Targets EMA committee issues positive opinion for Tesaro’s Zejula September 22, 2017Vol.43 No.35
Drugs & Targets Opdivo receives Japanese approval for advanced gastric cancer indications September 22, 2017Vol.43 No.35
In Brief NCI awards $12.4 million lymphoma research grant renewal to University of Iowa and Mayo Clinic September 22, 2017Vol.43 No.35
